EUCTR2015-005390-21-ES进行中（未招募）1 期
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab, gemcitabine, oxaliplatin and dexamethasone followed by Ibrutinib maitenance in patients with refractory/relapsed non-GCB diffuse large B-cell lymphoma non candidates to ASCT
GELTAMO0 个研究点目标入组 64 人开始时间: 2016年1月13日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 64
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Subjects with confirmed histologically diagnosis of diffuse large B-cell lymphoma.
- •2. Subjects must be 18 years of age or older.
- •3. Non-germinal center B-cell-like (GCB) subtype according to Hans algorithm (local laboratories).
- •A centralized evaluation by GEP will be carried out to confirm activated B-cell-like (ABC) subtype (commercial biotech lab to perform on paraphin samples), but a negative result will not exclude patient from the trial if a response is achieved after 4 cycles.
- •4. Relapsed or refractory disease after:
- •at least 1 prior line of therapy that includes rituximab in combination with chemotherapy, or,
- •after previous ASCT, or,
- •after reduced intensity conditioning allogeneic transplant, unless patient is receiving immunosuppressive drugs or active graft versus host disease is present at study entry.(Refractory disease is defined as failing to achieve CR after the most recent treatment.)
- •5. Eastern Cooperative Oncology Group (ECOG) performance status ? 2.
- •6. Baseline FDG-PET scan demonstrating positive lesions (Deauville 4 or 5) compatible with CT defined anatomical tumor sites.
- •7. Hematology values must be within the following limits:
- •a. absolute neutrophil count (ANC) ?1000/?L independent of growth factor support.
- •b. platelets ?100000/?L or ?50000/?L if bone marrow involvement independent of transfusion support in either situation.
- •8. Biochemical values within the following limits:
- •a. alanine aminotransferase (ALT) and aspartate aminotransferase (AST)
- •?2.5 x upper limit of normal (ULN).
- •b. total bilirubin ?1.5 x ULN unless bilirubin rise is due to Gilbert?s syndrome or of non-hepatic origin.
- •c. serum creatinine ?2 x ULN or estimated creatinine clearance (CCr) ?30 mL/min.
- •9. Women of childbearing potential and men who are sexually active must be practicing a highly effective method of birth control during and after the study consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials. Men must agree to not donate sperm during and after the study. For females, these restrictions apply for 1 month after the last dose of study drug. For males, these restrictions apply for 3 months after the last dose of study drug.
- •10. Women of childbearing potential must have a negative serum (beta-human chorionic gonadotropin [?-hCG]) or urine pregnancy test at Screening. Women who are pregnant or breastfeeding are ineligible for this study.
- •11. Sign (or their legally-acceptable representatives must sign) an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing and able to participate in the study.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 62
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 62
排除标准
- •1. Prior malignancy other than DLBCL, with the exception of adequately treated basal cell or squamous cell skin tumor, in situ cervical cancer, or other tumor from which the patient has been disease free for at least 2 years or which will not limit survival to < 2 years (Note: these cases must
- •be discussed with the Principal Investigator).
- •2. Candidates to autologous stem cell transplant.
- •3. Any life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the patient's safety, interfere with the absorption or metabolism of ibrutinib, or put the study outcomes at undue risk.
- •4. Significant cardiovascular disease such as uncontrolled or symptomatic
- •arrhythmias, congestive heart failure, or myocardial infarction within 6
- •months of screening, or any Class 3 or 4 cardiac disease as defined by
- •the New York Heart Association Functional Classification.
- •5. Malabsorption syndrome, disease significantly affecting gastrointestinal
- •function, or resection of the stomach or small bowel or ulcerative colitis,
- •symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.
- •6. Treatment with any immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 3 weeks before first dose of study drug (corticosteroids for disease-related symptoms allowed as indicated in section 2.7).
- •7. Prior treatment with ibrutinib or other BTK inhibitors.
- •8. Central nervous system (CNS) involvement by lymphoma.
- •9. History of stroke or intracranial hemorrhage within 6 months prior to randomization.
- •10. Requires anticoagulation with warfarin or equivalent Vitamin K antagonists.
- •11. Requires treatment with strong CYP3A inhibitors (see Section 2.7.1).
- •12. Grade ?2 toxicity (other than alopecia) related to prior anticancer therapy including radiation.
- •13. Known history of human immunodeficiency virus (HIV), active hepatitis C virus (HCV) (HCV; RNA polymerase chain reaction [PCR]-positive) or active Hepatitis B virus (HBV; DNA PCR-positive) infection or any uncontrolled active systemic infection requiring IV antibiotics. Subjects with PCR-negative HBV are permitted in the study.
- •14. Major surgery within 4 weeks before first dose of study drug.
- •15. Vaccinated with live, attenuated vaccines within 4 weeks of randomization.
- •16. Pregnancy or lactation
研究者
相似试验
进行中（未招募）
不适用
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.Mantle Cell LyphomaMedDRA version: 18.1Level: HLTClassification code 10026798Term: Mantle cell lymphomasSystem Organ Class: 100000004851EUCTR2015-004158-17-ESGELTAMO (Grupo Cooperativo Español de Llinfoma/Trasplante Autólogo de Médula Ósea)
进行中（未招募）
1 期
Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinical forms of Mantle Cell Lymphoma.MedDRA version: 20.0Level: PTClassification code: 10061275Term: Mantle cell lymphoma Class: 100000004864Mantle Cell LymphomaCTIS2024-512370-94-00Fundacion Geltamo50
进行中（未招募）
不适用
Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed lymphoma patients. - BeEAMDiagnosis of Non-Hodgkin lymphoma of any subtype, chronic lymphocytic leukemia, or Hodgkin disease either refractory or relapsed after at least one line of chemotherapy.MedDRA version: 9.1Level: HLGTClassification code 10025320MedDRA version: 9.1Level: HLGTClassification code 10025319EUCTR2008-002736-15-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
进行中（未招募）
不适用
study to evaluate the efficacy of a preparative regimen for transplantation in refractory/relapsed non-Hodgkin lymphoma patients.Adult agressive B-cell non-Hodgkin lymphoma patients.MedDRA version: 14.1Level: HLGTClassification code 10025320Term: Lymphomas non-Hodgkin's B-cellSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10012821Term: Diffuse large B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: SOCClassification code 10005329Term: Blood and lymphatic system disordersSystem Organ Class: 10005329 - Blood and lymphatic system disordersMedDRA version: 14.1Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-001246-14-ITAZIENDA OSPEDALIERA OSPEDALE S. SALVATORE
进行中（未招募）
不适用
A multicentre phase II trial to determine the efficacy of the anti-tyrosine kinase sunitinib (SUTENT®) as second line therapy in patients with transitional cell carcinoma (TCC) of the urothelium which failed or progressed after first line chemotherapy for advanced or metastatic disease. - VESSHistologically proven advanced TCC (transitional cell carcinoma) of the urotheliumMedDRA version: 9.1Level: LLTClassification code 10044420Term: Transitional cell carcinoma of the bladder stage unspecifiedEUCTR2008-001004-22-FRCentre René Huguenin